Cangene Corporation - Product Pipeline Review - 2012

Global Markets Direct, July 2012, Pages: 39

Cangene Corporation – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Cangene Corporation - Product Pipeline Review - 2012” provides data on the Cangene Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Cangene Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Cangene Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cangene Corporation - Brief Cangene Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cangene Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cangene Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cangene Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Cangene Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cangene Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cangene Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cangene Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cangene Corporation and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Cangene Corporation; Cangene Corporation - Key Therapeutics; Cangene Corporation - Pipeline Overview and Promising Molecules; Cangene Corporation - News; Cangene Corporation - Latest Updates; Cangene Corporation - Pipeline; Cangene Corporation - Discontinued/Dormant Projects

2
List of Tables 4
List of Figures 4
Cangene Corporation Snapshot 5
Cangene Corporation Overview 5
Key Information 5
Key Facts 5
Cangene Corporation – Research and Development Overview 6
Key Therapeutic Areas 6
Cangene Corporation – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Cangene Corporation – Pipeline Products Glance 10
Cangene Corporation – Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
Cangene Corporation – Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Cangene Corporation – Drug Profiles 12
Anthrax Immune Globulin 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Botulism Antitoxin Heptavalent 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Ebola/Marburg Immune Globulins 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Immune Globulin Intravenous Program 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Ricin Immune Globulin 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Cangene Corporation – Pipeline Analysis 18
Cangene Corporation – Pipeline Products by Therapeutic Class 18
Cangene Corporation – Pipeline Products by Route of Administration 19
Cangene Corporation – Recent Pipeline Updates 20
Cangene Corporation - Dormant Projects 21
Cangene Corporation - Discontinued Pipeline Products 22
Discontinued Pipeline Product Profiles 22
PEP 35 22
Cangene Corporation – Company Statement 23
Cangene Corporation – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Cangene Corporation - Key Manufacturing Facilities 27
Cangene Corporation, Recent Developments 28
Cangene Corporation- Press Release 28
May 29, 2012: Cangene Initiates Voluntary Recall Of Finished Product From Single HepaGam B Manufacturing Bulk Lot 28
Dec 18, 2009: Cangene Receives European Positive Opinion For Hepatitis B Product 28
Oct 19, 2009: Cangene acquires U.S. commercialization rights for HepaGam B from Apotex 29
Jun 04, 2009: Cangene receives first overseas approval for HepaGam B 29
Jun 04, 2009: Cangene Receives First Overseas Approval For HepaGam B 30
Financial Deals Landscape 31
Cangene Corporation, Deals Summary 31
Cangene Corporation, Pharmaceuticals & Healthcare, Deal Details 32
Partnerships 32
Upfront Chromatography Enters Into Co-Development Agreement With Cangene 32
Baxter Schweiz Enters Into Co-Marketing Agreement With Cangene 33
Licensing Agreements 34
Upfront Chromatography Enters Into License Agreement With Cangene 34
Equity Offering 35
Cangene Completes Public Offering Of $31 Million 35
Acquisition 37
Cangene Acquires Twinstrand Therapeutics 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Cangene Corporation, Key Information 5
Cangene Corporation, Key Facts 5
Cangene Corporation – Pipeline by Indication, Select 7
Cangene Corporation – Pipeline by Stage of Development, Select 8
Cangene Corporation – Monotherapy Products in Pipeline, Select 9
Cangene Corporation – Phase III, Select 10
Cangene Corporation – Pre-Clinical, Select 11
Cangene Corporation – Pipeline By Therapeutic Class, Select 18
Cangene Corporation – Pipeline By Route of Administration, Select 19
Cangene Corporation – Recent Pipeline Updates, Select 20
Cangene Corporation - Dormant Developmental Projects,Select 21
Cangene Corporation - Discontinued Pipeline Products, Select 22
Cangene Corporation, Other Locations 25
Cangene Corporation, Subsidiaries 26
Cangene Corporation, Key Manufacturing Facilities 27
Cangene Corporation, Deals Summary 31
Upfront Chromatography Enters Into Co-Development Agreement With Cangene 32
Baxter Schweiz Enters Into Co-Marketing Agreement With Cangene 33
Upfront Chromatography Enters Into License Agreement With Cangene 34
Cangene Completes Public Offering Of $31 Million 35
Cangene Acquires Twinstrand Therapeutics 37

List of Figures
Cangene Corporation – Pipeline by Indication, Select 7
Cangene Corporation – Pipeline by Stage of Development, Select 8
Cangene Corporation – Monotherapy Products in Pipeline, Select 9
Cangene Corporation – Pipeline By Therapeutic Class, Select 18

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Scientific Games Corporation - Company Analysis
• Altera Corporation
• Bose Corporation
• SYNNEX Corporation
• Avocent Corporation - SWOT Analysis
• Black & Decker Corporation - SWOT Analysis
• SanDisk Corporation
• Nortel Networks Corporation
• Ixia - Company Analysis